Particularly, the frequency of PRSS56 overexpression in gastrointestinal cancer was 8.8% in esophagus cancer, 11.6% in gastric cancer, 32.1% in colon cancer, 44.1% in rectal cancer, and 15.1% in liver cancer, respectively. Here, PRSS56 is linked to rectal cancer.